Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Metastatic Breast Cancer
Conditions
Keywords
metastatic breast cancer, HER2/neu negative, paclitaxel, bevacizumab, liposomal doxorubicine, capecitabine
Brief summary
An open randomized phase III study to compare 8 continuous cycles of chemotherapy with 8 cycles of intermittent (2 times 4 cycles) chemotherapy in first line treatment, in combination with bevacizumab, and second line treatment of patients with HER2/neu negative, incurable, metastatic or unresectable locally advanced breast cancer.
Detailed description
The primary goal of this non-inferiority trial is to determine if the results obtained with a intermittent chemotherapy regimen (2 x 4 cycles of paclitaxel) are not inferior to the results of a continuous chemotherapy regimen (8 cycles of paclitaxel), both combined with bevacizumab in first line treatment of patients with HER2/neu negative, incurable, metastatic or unresectable locally advanced breast cancer.
Interventions
DRUGPaclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine
1. st line: * Paclitaxel and bevacizumab: 8 cycles, unless PD or unacceptable toxicity occurs earlier. * Bevacizumab until PD or unacceptable toxicity * At PD patients will go to the 2nd treatment line. 2. nd line: * Non-pegylated liposomal doxorubicin (Myocet®) (or capecitabine): 8 cycles, unless PD or unacceptable toxicity occurs earlier. * At PD patients will go to the 3rd treatment line. If possible, it is advised to cross-over from 2nd line non-pegylated liposomal doxorubicin to 3rd line capecitabine.
Sponsors
Roche Pharma AG
Teva Pharma
Borstkanker Onderzoek Groep
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Female patients ≥ 18 years old. * Patients with HER2/neu negative, incurable, metastatic or unresectable locally advanced breast cancer, who are candidates for chemotherapy. * Patients with measurable or evaluable-only (RECIST 1.1) * Documented Estrogen Receptor (ER) / Progesteron Receptor (PR) status. * HER2/neu-negative disease * Patients with an ECOG Performance Status ≤ 2. * Life expectancy of \> 12 weeks. * Signature of Informed Consent Form
Exclusion criteria
* Previous chemotherapy for HER2/neu negative, incurable, metastatic or unresectable locally advanced breast cancer. * Prior hormonal therapy for HER2/neu negative, incurable, metastatic or unresectable locally advanced breast cancer that has not been discontinued 1 week before start of study treatment. * Prior adjuvant/neo-adjuvant chemotherapy within 6 months prior to first study treatment. However, if the prior adjuvant/neo-adjuvant chemotherapy was taxane based, patients are excluded if they received their last chemotherapy within12 months prior to first study treatment. * Prior radiotherapy covering more than 30% of marrow-bearing bone. * Patients that have received recent radiation therapy that are not recovered from any significant (Grade ≥ 3) acute toxicity prior to study treatment. * Prior therapy with bevacizumab, sorafenib, sunitinib, or other VEGF pathway-targeted therapy. * Chronic daily treatment with aspirin * Chronic daily treatment with corticosteroids, with the exception of inhaled steroids. * Current or recent treatment with another investigational drug or participation in another investigational study. * Inadequate bone marrow, liver, renal function * INR \> 1.5 or an aPTT \> 1.5 x ULN within 7 days prior to first study treatment. * Known CNS disease, except for treated brain metastases. * Patients with concurrent active malignancy * Pregnant or lactating * Women of childbearing potential not using effective, non-hormonal means of contraception * Major surgical procedure (including open biopsy) within 28 days prior to the first study treatment * Core biopsy or other minor surgical procedure, within 7 days prior to day 1. * Significant vascular disease within 6 months prior to day 1. * Any previous venous thrombo-embolism \> CTC Grade 3. * History of haemoptysis * History or evidence of inherited bleeding diathesis or coagulopathy with the risk of bleeding. * Uncontrolled hypertension * Clinically significant (i.e. active) cardiovasculair disease * LVEF by MUGA or ECHO \< 50%. * History of abdominal fistula, Grade 4 bowel obstruction or GI perforation, intra-abdominal abscess within 6 months of randomization. * Serious non-healing wound, peptic ulcer or bone fracture. * Known hypersensitivity to any of the study drugs or excipients. * Hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies. * Psychiatric illness, physical examination or laboratory findings that may interfer with protocol
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression free survival | 1 year | PFS is defined as the time from start of treatment to the documented progression that requires the patient to switch to the next treatment line or to death due to any cause. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective overall response rate | 1 year | To compare the objective Overall Response Rate (ORR) between 8 continuous cycles of chemotherapy with 8 cycles of intermittent (2 times 4 cycles) chemotherapy in first treatment line, combined with bevacizumab, and in second treatment line. ORR calculated as the proportion of patients with a best overall response of confirmed Complete Response (CR) and Partial Response (PR). |
| Duration of objective response | 1 year | To compare the Duration of Objective Response (DOR) between 8 continuous cycles of chemotherapy with 8 cycles of intermittent (2 times 4 cycles) chemotherapy in first treatment line, combined with bevacizumab, and second treatment line; For the intermittent chemotherapy schedule the first DOR and, if applicable, second DOR in the same treatment line will be accumulated DOR calculated as the time from the date of first documented CR or PR to the first documented progression or death due to underlying cancer |
| Overall survival | 1 year | To compare Overall Survival (OS) between 8 continuous cycles of chemotherapy with 8 cycles of intermittent (2 times 4 cycles) chemotherapy. OS calculated as the time from the date of randomization to the date of death due to any cause or the date of last contact |
| Progression free survival second line treatment | 1 year | To compare the PFS of second line treatment of 8 continuous cycles of chemotherapy with liposomal doxorubicin (or capecitabine) with 8 cycles of intermittent (2 times 4 cycles) chemotherapy with liposomal doxorubicin (or capecitabine); |
| Quality of life measures | 1 year | To compare the Quality of Life (QoL) between 8 continuous cycles of chemotherapy with 8 cycles of intermittent (2 times 4 cycles) chemotherapy. Changes in the RAND 36 quality of life scale will be measured |
| Pharmacoeconomics | 1 year | To compare the Pharmacoeconomics between 8 continuous cycles of chemotherapy with 8 cycles of intermittent (2 times 4 cycles) chemotherapy. Direct medical costs will be calculated using a standard cost method. |
| Safety and tolerability. The total number of grade 3 and 4 adverse events will be analyzed. | 1 year | To compare the Safety between 8 continuous cycles of chemotherapy with 8 cycles of intermittent (2 times 4 cycles) chemotherapy The total number of grade 3 and 4 adverse events will be analyzed as a measure of safety and tolerability |
Countries
Netherlands
Outcome results
None listed